Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPAZ: Tucatinib + Pembrolizumab + Trastuzumab in HER2+ BCBM
NCT04512261Phase 2Withdrawn
- Sponsor
- Ellison Institute of Technology
- Start
- Jun 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucatinib in HER2-positive breast cancer, sponsored by Ellison Institute of Technology. Planned start Jun 2022; status: withdrawn.
02
Drugs
tucatinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04512261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04512261.